Alan Packard's laboratory is engaged in the development of transition-metal based radiopharmaceuticals for cancer imaging and therapy. The focus of the imaging program is on the development of Cu-64-based PET agents that can be used to non-invasively evaluate the multidrug resistance status of patients with breast and other types of cancer. These new copper complexes are, like the MDR chemotherapeutics, substrates for Pgp, the protein implicated in MDR1 multidrug resistance.
Dr. Packard and colleagues are also developing new antibody/chelate conjugates for use in attaching Cu-64 (and other diagnostic and therapeutic radionuclides) to engineered antibody fragments. In collaboration with Mark Kieran at Dana-Farber Cancer Institute, they are evaluating new imaging agents targeted to the vitronectin receptor for directly monitoring clinical response to anti-angiogenesis therapy.
About Alan Packard
Alan Packard received his PhD from Colorado State University and completed a fellowship at the University of Cincinnati.
Dr. Packard is currently Vice-President, Radiopharmaceutical Sciences Council, Society of Nuclear Medicine.
Kiani S, Staples RJ, Packard AB. A lariat-functionalized copper(II) diimine-dioxime complex. Acta Crystallographica. Section C, Crystal Structure Communications 2002; 58: m593-595.
Packard AB, Kronauge JF, Barbarics E, Kiani S, Treves ST. Synthesis and biodistribution of a Lipophilic Cu-64-labeled monocationic Copper(II) complex. Nuclear Medicine and Biology 2002; 29: 289-294.
Treves ST, Packard AB, Fung LC. Assessment of rapid changes in renal blood flow with (191m)Ir, an ultra-short-lived radionuclide. Journal of Nuclear Medicine 2004; 45: 508-511.